No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials. [PDF]
Arthritis Res TherRamiro S +6 more
europepmc +1 more source
Spotlight: What's New in JEADV – Editor‐in‐Chief's Selection
JEADV Clinical Practice, Volume 5, Issue 2, Page 367-372, June 2026.
Carle Paul
wiley +1 more source
Retention, Effectiveness, and Safety of Secukinumab in Plaque Psoriasis: 5-Year Results from SERENA. [PDF]
Dermatol Ther (Heidelb)Augustin M +14 more
europepmc +1 more source
Efficacy and Safety of Xeligekimab Compared to Other IL-17A Inhibitors for Chinese Patients with Moderate-to-severe Plaque Psoriasis: A Matching-adjusted Indirect Comparisons. [PDF]
Acta Derm VenereolDing Y, Liu W.
europepmc +1 more source
Systemic inflammatory response drives post-cardiac arrest multi-organ injury via IL-17 signaling in murine and porcine models. [PDF]
Front ImmunolYan Y +8 more
europepmc +1 more source
Complete Skin Remission of Lichen Planus With Tirzepatide
Australasian Journal of Dermatology, Volume 67, Issue 4, Page e265-e266, June 2026.
Harmeet Bhullar +4 more
wiley +1 more source
A Narrative Review of Secukinumab in Spondyloarthritis and Psoriatic Arthritis: Treating the Whole Patient. [PDF]
Rheumatol TherKaeley GS +5 more
europepmc +1 more source
Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. [PDF]
CureusAbdullah A, Polus L.
europepmc +1 more source
Acute erythrodermic psoriasis complicated by systemic capillary leak syndrome following secukinumab therapy: a case report. [PDF]
Front ImmunolXu R, Gao X, Zhang L.
europepmc +1 more source
Real-world skin and dermatology-specific quality-of-life outcomes and a nomogram to predict skin response to secukinumab in Chinese psoriatic arthritis patients: a multicenter retrospective cohort study. [PDF]
Front Med (Lausanne)Zhang L, Xu Z, Gong J, Tao X, Hu F.
europepmc +1 more source